Manulife (Manufacturers Life Insurance)
LCTX icon

Manulife (Manufacturers Life Insurance)’s Lineage Cell Therapeutics LCTX Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-57,953
Closed -$52.5K – 2998
2024
Q3 		$52.5K Hold
57,953
– – ﹤0.01% 2983
2024
Q2 		$57.8K Sell
57,953
-430
-0.7% -$475 ﹤0.01% 2940
2024
Q1 		$86.4K Hold
58,383
– – ﹤0.01% 2812
2023
Q4 		$63.6K Sell
58,383
-2,770
-5% -$3.03K ﹤0.01% 2900
2023
Q3 		$72.2K Hold
61,153
– – ﹤0.01% 2893
2023
Q2 		$86.2K Buy
+61,153
New +$84.5K ﹤0.01% 2896
2022
Q2 		– Sell
-59,658
Closed -$91.9K – 3079
2022
Q1 		$91.9K Sell
59,658
-16,410
-22% -$25.5K ﹤0.01% 2969
2021
Q4 		$186 Buy
76,068
+1,077
+1% +$2.52K ﹤0.01% 2920
2021
Q3 		$189K Sell
74,991
-3,053
-4% -$7.83K ﹤0.01% 3006
2021
Q2 		$222K Buy
+78,044
New +$202K ﹤0.01% 3029
2020
Q2 		– Sell
-83,293
Closed -$69K – 2892
2020
Q1 		$69K Buy
83,293
+46,790
+128% +$46.6K ﹤0.01% 2672
2019
Q4 		$32K Buy
+36,503
New +$30.4K ﹤0.01% 2855
2019
Q2 		– Sell
-81,690
Closed -$107K – 2943
2019
Q1 		$107K Buy
81,690
+14,802
+22% +$18.4K ﹤0.01% 2569
2018
Q4 		$62K Sell
66,888
-11,840
-15% -$18.1K ﹤0.01% 2476
2018
Q3 		$162K Sell
78,728
-12,360
-14% -$26K ﹤0.01% 2818
2018
Q2 		$164K Buy
91,088
+8,587
+10% +$17.3K ﹤0.01% 3264
2018
Q1 		$194K Sell
82,501
-2,219
-3% -$5.2K ﹤0.01% 3038
2017
Q4 		$160K Buy
84,720
+9,139
+12% +$20K ﹤0.01% 3182
2017
Q3 		$189K Buy
75,581
+878
+1% +$2.18K ﹤0.01% 3025
2017
Q2 		$206K Buy
74,703
+4,730
+7% +$13.2K ﹤0.01% 2986
2017
Q1 		$212K Buy
69,973
+9,484
+16% +$26.9K ﹤0.01% 2795
2016
Q4 		$191K Sell
60,489
-2,023
-3% -$6.21K ﹤0.01% 2822
2016
Q3 		$214K Buy
62,512
+1,589
+3% +$4.39K ﹤0.01% 2728
2016
Q2 		$139K Buy
60,923
+15,574
+34% +$38.2K ﹤0.01% 3013
2016
Q1 		$110K Sell
45,349
-770
-2% -$1.72K ﹤0.01% 3003
2015
Q4 		$141 Hold
46,119
– – ﹤0.01% 2908
2015
Q3 		$112 Hold
46,119
– – ﹤0.01% 3071
2015
Q2 		$135 Sell
46,119
-3,138
-6% -$12.2K ﹤0.01% 3181
2015
Q1 		$198 Sell
49,257
-1,700
-3% -$5.88K ﹤0.01% 2746
2014
Q4 		$153 Buy
50,957
+7,071
+16% +$19.1K ﹤0.01% 2839
2014
Q3 		$111 Sell
43,886
-2,639
-6% -$6.35K ﹤0.01% 3044
2014
Q2 		$114K Buy
46,525
+6,558
+16% +$14.8K ﹤0.01% 3108
2014
Q1 		$106 Buy
39,967
+2,892
+8% +$8.52K ﹤0.01% 3048
2013
Q4 		$108 Buy
37,075
+487
+1% +$1.47K ﹤0.01% 3038
2013
Q3 		$113 Sell
36,588
-426
-1% -$1.35K ﹤0.01% 3002
2013
Q2 		$118K Buy
+37,014
New +$119K ﹤0.01% 2946

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s LCTX Position: Q4 2024 in Review

Manulife (Manufacturers Life Insurance) sold out of Lineage Cell Therapeutics (LCTX) in Q4 2024, closing a stake of 57,953 shares — an estimated $52.5K sold.

Manulife (Manufacturers Life Insurance) first reported a position in LCTX in Q2 2013 and held it in 36 quarters. The position peaked at $222K in Q2 2021. 126 funds tracked by Wall St. Rank hold LCTX as of Q4 2024.

  • Manulife (Manufacturers Life Insurance) reported no remaining Lineage Cell Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Manulife (Manufacturers Life Insurance) sold 57,953 Lineage Cell Therapeutics shares in Q4 2024, an estimated $52.5K.
  • Manulife (Manufacturers Life Insurance) first reported a position in Lineage Cell Therapeutics in Q2 2013 and held it in 36 quarters.
  • Manulife (Manufacturers Life Insurance)'s Lineage Cell Therapeutics position peaked at $222K in Q2 2021.
  • 126 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2024.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q4 2024, filed 14 Feb 2025.